Advertisement

Antithrombotika und Antihämorrhagika

  • Lutz Hein

Zusammenfassung

In der Gruppe der Antithrombotika sind die Gesamtverordnungen der Thrombozytenaggregationshemmer im Jahr 2013 um weniger als 1% und der Antikoagulantien um 8% angestiegen. Erstmalig haben die Verordnungen der Vitamin-K-Antagonisten gegenüber dem Vorjahr abgenommen, während die Verordnungen der Thrombinund Faktor Xa-Antagonisten um 180% zugenommen haben. Dabigatran und Rivaroxaban erreichten 24% der Verordnungen der oralen Antikoagulantien. Bei den Thrombozytenaggregationshemmern stieg der Verordnungsanteil von Prasugrel und Ticagrelor auf 14% der ADP-Rezeptorantagonisten. Bei den Antihämorrhagika sind die Faktor-VIII-Präparate die umsatzstärkste Gruppe.

Literatur

  1. Algra A, de Schryver EL, van Gijn J, Kappelle LJ, Koudstaal PJ (2001): Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin. Cochrane Database Syst Rev 2001 (4): CD 001342Google Scholar
  2. Antithrombotic Trialists' Collaboration (2002): Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Brit Med J 324: 71–86Google Scholar
  3. Bauer KA (2012): Reversal of antithrombotic agents. Am J Hematol 87: S119–S126PubMedCrossRefGoogle Scholar
  4. Bhatt DL, Fox KAA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ; CHARISMA Investigators (2006): Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354: 1706–1717PubMedCrossRefGoogle Scholar
  5. Bonello L, Laine M, Kipson N, Mancini J, Helal O, Fromonot J, Gariboldi V, Condo J, Thuny F, Frere C, Camoin-Jau L, Paganelli F, Dignat-George F, Guieu R (2014): Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol 63: 872–877PubMedGoogle Scholar
  6. Bowry ADK, Brookhart MA, Choudhry NK (2008): Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared with antiplatelet monotherapy for the prevention of vascular events. Am J Cardiol 101: 960–966PubMedCrossRefGoogle Scholar
  7. CAPRIE Steering Committee (1996): A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329–1339Google Scholar
  8. Cattaneo M, Schulz R, Nylander S (2014): Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol 63: 2503–2509PubMedCrossRefGoogle Scholar
  9. Chan FK, Ching JY, Hung LC, Wong VW, Leung VK, Kung NN, Hui AJ, Wu JC, Leung WK, Lee VW, Lee KK, Lee YT, Lau JY, To KF, Chan HL, Chung SC, Sung JJ (2005): Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 352: 238–244PubMedCrossRefGoogle Scholar
  10. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, Bensimon G, Funck-Brentano C, Montalescot G (2009): Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373: 309–317PubMedGoogle Scholar
  11. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators (2009): Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 361: 1139–1151Google Scholar
  12. De Schryver ELLM, Algra A, van Gijn MD (2003): Cochrane Review: Dipyridamole for preventing major vascular events in patients with vascular disease. Stroke 34: 2072–2080PubMedGoogle Scholar
  13. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ; MATCH investigators (2004): Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364: 331–337PubMedGoogle Scholar
  14. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A (1996): European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143: 1–13PubMedCrossRefGoogle Scholar
  15. Eikelboom JW, Anand SS, Maimberg K, Weitz JI, Ginsberg JS, Yusuf S (2000): Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 355: 1936–1942PubMedGoogle Scholar
  16. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S (2003): Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105: 1650–1655Google Scholar
  17. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt JU, Simoons ML, Van de Werf F; RE-ALIGN Investigators (2013): Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 369: 1206–1214PubMedCrossRefGoogle Scholar
  18. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W, RECORD1 Study Group (2008): Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 358: 2765–2775Google Scholar
  19. European Medicines Agency (2011): Updates on safety of PRADAXA; Pressemitteilung vom 18. Nov. 2011.Internet : www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/11/WC500117818.pdf
  20. Gemeinsamer Bundesausschuss (2012): Bekanntmachung des Beschlusses des Gemeinsamen Bundesausschusses. Ticagrelor. Bundesanzeiger 11: S254Google Scholar
  21. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators (2011): Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365: 981–992Google Scholar
  22. Grau E, Tenias JM, Real E, Medrano J, Ferrer R, Pastor E, Selfa S (2001): Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism. Am J Hematol 67: 10–14PubMedCrossRefGoogle Scholar
  23. Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, O’Gara P, Whitlow P; American Heart Association; American College of Cardiology; Society for Cardiovascular Angiography and Interventions; American College of Surgeons; American Dental Association; American College of Physicians (2007): Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 115: 813–818PubMedCrossRefGoogle Scholar
  24. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ (2001): Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88: 230–235PubMedCrossRefGoogle Scholar
  25. Harper P, Young L, Merriman E (2012): Bleeding risk with dabigatran in the frail elderly. N Engl J Med 366: 864–867CrossRefGoogle Scholar
  26. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS (2009): Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301: 937–944PubMedGoogle Scholar
  27. Hoots WK, Nugent DJ (2006): Evidence for the benefits of prophylaxis in the management of hemophilia A. Thromb Haemost 96: 433–440PubMedGoogle Scholar
  28. Jneid H, Bhatt DL, Corti R, Badimon JJ, Fuster V, Francis GS (2003): Aspirin and clopidogrel in acute coronary syndromes. Therapeutic insights from the CURE study. Arch Intern Med 163: 1145–1153PubMedCrossRefGoogle Scholar
  29. Jones L, Griffin S, Palmer S, Main C, Orton V, Sculpher M, Sudlow C, Henderson R, Hawkins N, Riemsma R (2004): Clinical effectiveness and cost-effectiveness of clopidogrel and modified- release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. Health Technol Assess (38): iii-iv, 1–196Google Scholar
  30. Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, Henry DA, Kopp A, Mamdani MM., Szmitko PE, Austin PC, Tu JV, Henry DA, Kopp A, Mamdani MM. (2009): A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180: 713–718PubMedCentralPubMedGoogle Scholar
  31. Keng TB (2001): Heparin-induced thrombocytopenia and thrombosis syndrome: in vivo cross-reactivity with danaparoid and successful treatment with r-Hirudin. Br J Haematol 114: 394–396PubMedCrossRefGoogle Scholar
  32. Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH (1996): Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 334: 682–687PubMedCrossRefGoogle Scholar
  33. Kwok CS, Loke YK (2010): Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther 31: 810–823PubMedGoogle Scholar
  34. Larsen TB, Rasmussen LH, Skjøth F, Due KM, Callréus T, Rosenzweig M, Lip GY (2013): Efficacy and safety of dabigatran etexilate and warfarin in „real-world“ patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 61: 2264–2273PubMedGoogle Scholar
  35. Lensing AWA, Prins MH, Davidson BL, Hirsh J (1995): Treatment of deep venous thrombosis with low-molecular-weight heparins: a meta-analysis. Arch Intern Med 155: 601–607PubMedCrossRefGoogle Scholar
  36. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M. (1996): A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 334: 677–681PubMedCrossRefGoogle Scholar
  37. Martel N, Lee J, Wells PS (2005): Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 106: 2710–2715PubMedCrossRefGoogle Scholar
  38. Mehta SR, Yusuf S, Peters RJG, Bertrand ME, Lewis BL, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. (2001): Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients underoing percutaneous coronary intervention: The PCI-CURE study. Lancet 358: 527–533PubMedGoogle Scholar
  39. Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ (2012): Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 110: 453–460PubMedCrossRefGoogle Scholar
  40. Mismetti P, Laporte S, Darmon J-Y, Buchmüller A, Decousus H (2001): Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 88: 913–930PubMedCrossRefGoogle Scholar
  41. Neubauer H, Krüger JC, Lask S, Endres HG, Pepinghege F, Engelhardt A, Bulut D, Mügge A (2009): Comparing the antiplatelet effect of clopidogrel hydrogensulfate and clopidogrel besylate: a crossover study. Clin Res Cardiol 98: 533–540PubMedCrossRefGoogle Scholar
  42. Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW, Han KH, Park SW, Yun SC, Lee SG, Rha SW, Seong IW, Jeong MH, Hur SH, Lee NH, Yoon J, Yang JY, Lee BK, Choi YJ, Chung WS, Lim DS, Cheong SS, Kim KS, Chae JK, Nah DY, Jeon DS, Seung KB, Jang JS, Park HS, Lee K (2010): Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 362: 1374–1382PubMedCrossRefGoogle Scholar
  43. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators (2011): Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 365: 883–891PubMedCrossRefGoogle Scholar
  44. Silber S, Borggrefe M, Hasenfuß G et al (2010): Kommentare zu den Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zur Diagnostik und Therapie von Patienten mit ST-Streckenhebungsinfarkt (STEMI). Kardiologie 4: 84–92Google Scholar
  45. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N, Becquemont L; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators (2009): Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360: 363–375PubMedCrossRefGoogle Scholar
  46. Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding (2013): N Engl J Med 368: 1272–1274PubMedCrossRefGoogle Scholar
  47. Stangier J, Rathgen K, Stahle H, Mazur D (2010): Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel- group, single- centre study. Clin Pharmacokinet. 49: 259–268PubMedCrossRefGoogle Scholar
  48. The ACTIVE Investigators (2009): Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 360: 2066–2078Google Scholar
  49. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (2001): Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation. N Engl J Med 345: 494–502Google Scholar
  50. The ESPRIT Study Group (2006): Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367: 1665–1673Google Scholar
  51. The Warfarin Antiplatelet Vascular Evaluation Trial Investigators (2007): Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 357: 217–227Google Scholar
  52. Van de Werf F, Bax J, Betriu A. Blomstrom-Lundqvist, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M; ESC Committee for Practice Guidelines (CPG) (2008): Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 29: 2909–2945Google Scholar
  53. Van der Heijden JF, Hutten BA, Büller HR, Prins MH (2002): Vitamin K antagonists or low-molecular- weight heparin for the long term treatment of symptomatic venous thromboembolism (Cochrane Reviews). In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software.Google Scholar
  54. Walenga JM (2002): Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb Res 105: 401–405PubMedCrossRefGoogle Scholar
  55. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsén M (2009): Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361: 1045–1057PubMedCrossRefGoogle Scholar
  56. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, Wang C, Li H, Meng X, Cui L, Jia J, Dong Q, Xu A, Zeng J, Li Y, Wang Z, Xia H, Johnston SC; CHANCE Investigators (2013): Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 369: 11–19PubMedGoogle Scholar
  57. White RH, Ginsberg JS (2003): Low-molecular-weight heparins: are thy all the same? Br J Hematol 121: 12–20CrossRefGoogle Scholar
  58. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators (2007): Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357: 2001– 2015Google Scholar
  59. Zed PJ, Tisdale JE, Borzak S (1999): Low-molecular-weight heparins in the management of acute coronary syndromes. Arch Intern Med 159: 1849–1857PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Lutz Hein
    • 1
  1. 1.Institut für Experimentelle und Klinische Pharmakologie und ToxikologieAlbert-Ludwig-UniversitätFreiburg

Personalised recommendations